Search 

AEBi was established in the year 2000, and has been managed since then based on the idea that the ability to manipulate and design peptides has vastly superior advantages to many, if not any, existing and trajectory technologies of drug development. This idea is valid today as well.The basic idea is that we do not require a natural lead or a sequence (usually coming from the academia or other research) which are either not strong enough or not specific enough and difficult to manipulate in order to create a drug.
An artificial high complexity pool, representing a broad spectrum of  possibilities, manipulated by our technology, will provide the best possible solution. Such a  solution  will not be hindered or blocked by natural interactions and will be very specific to the problem.
AEBi, a development-stage biopharmaceutical company engaged in discovery and development of therapeutic peptides, has developed a combinatorial biology screening platform technology (IP protected).
The major advantage is that it can be used not only to find binders to known targets, but to select the best functional molecules among them. AEBi's platform is very flexible, exploiting combinatorial biology to discover new and better lead compounds to disease targets.

Our Breakthrough SoAP Platform:
-------------------------------------------------
Our platform provides functional leads to very difficult targets (functional leads - agonist, antagonist, inhibitor, etc.), not merely those that best bind with the target.

Moreover, it allows us to develop drugs to many illnesses, among them CANCER and COVID19, and is expected to transform the drug discovery R&D phase by significantly reducing the attrition rate of new drug candidates.
This Breakthrough technology generates very specific lead compounds with greater functionality and improved pharmacological properties. Such lead Compounds will allow more effective drugs and fewer side effects. The need for such technology is acute and pressing for many reasons. The sole external requirement in the screening process is a Defined Target (usually an illness-related protein).

MuTaTo: our Multiple Targeted Comprehensive Cancer Therapy
-------------------------------------------------------------------------------------
This new cancer treatment is a personalized medicine concept, that can be also turned into a "shelf product". The main principal of it is using multiple targeting peptides connected together with a toxin. The main advantage of it is that it would lower the probability of the targeted cancer cells to develop drug-resistance due to mutations they possess, and at the same time would lower adverse effects due to avidity effect. Each cancer patient would receive a specific drug perfectly suited to his/her cancer, based on the expression profile of receptors on the outer membrane of their cancer cells. This therapy's construct production is easy and rapid. Therefore, the production cost would not be as expensive as with other biological drugs, or other sophisticated cancer treatments.
MuTaTo our Multiple Targeted Safe Cancer Therapy is DIFFERENT and UNIQUE because:
----------------------------------------------------------------
1- It is EFFECTIVE on almost all types of CANCERS because we will develop a MuTaTo molecule for every type of cancers.
2- it is SAFE on healthy cells and DOESN'T cause any suffering to patients.
3- unlike other cancer therapies that attack cancer from only one or 2 targets at most , MuTaTo is DIFFERENT because it attacks cancer from at least 3 targets so that cancer DOESN'T metastasize nor develop drug resistance.
4- MuTaTo can treat almost all types of cancers even rare one and is effective on all cancer stages even terminal ones.
5- our MuTaTo is so versatile it can be:
a) used as personalized Cancer therapy where each cancer patient would receive a specific drug perfectly suited to his/her cancer, based on the expression profile of receptors on the outer membrane of their cancer cells.
b) or it can be mass produced as a "shelf Product - Oncolytic Drug" to treat different cancers with different indications, so we will have not just one MuTaTo Drug, but a COMPLETE FAMILY OF MuTaTo DRUGS, to treat almost all types and indications of Cancers , from all stages, even rare and Terminal cancers.

Our MUTATO Cancer treatment is PATENTED,
https://patents.google.com/patent/WO2018061004A1/en?inventor=Ilan+morad&oq=Ilan+morad

Our PLATFORM is patented
https://patents.google.com/patent/WO2007010525A3/en?inventor=Ilan+morad&oq=Ilan+morad

Our concept is peer approved and we have proof of concept, and published in the prestigious Cancer Therapy Magazine
https://m.scirp.org/papers/98400

-Chinese Journals have written about our concept including MyBioGate
https://mp.weixin.qq.com/s/NYjbJDgdBOtxsAztKr7wMw
独家回访 | 一年内彻底治愈癌症,炒作还是事实？
徐子宜 Ginger 美柏企业服务
here is one article about us in another journal:
https://www.myzaker.com/article/5f88ec9f32ce40ea2900000a

Acon Pharmaceuticals Inc. (Acon Pharma) is a specialty pharmaceutical company and focuses on BLA, ANDA, and 505(b)(2) NDA drug product development with its captive drug delivery system technology platforms. Acon Pharma provides service to its partners and customers to accelerate their IND and NDA product development by out-licencing its captive drug delivery platforms, pre-formulation, formulation, process development, and manufacturing of different types of dosage forms and drug delivery products. Our expertise covers drug development and delivery of poorly soluble small molecule drugs, siRNA, oligonucleotides, peptides, protein, and plasmid DNA. Our formulation technology platforms include nanoparticles, microspheres / microparticles, nanocrystals, liposome, implant, long-acting injectable, oral fast dissolving film (ODF), transdermal patches, resinate / polistirex suspension, nasal spray, topical cream, gel, ointment, nanoemulsion, microemulsion, self-emulsifying system, tablets, capsules, inhalers, controlled release, modified release, and delayed release.

Aequor discovered a new genus and several new species of marine microbes that produce “green,” non-toxic chemicals that target Gram-negative and Gram-positive bacteria and fungi, and uniquely remove biofilm in minutes and prevent biofilm formation for long periods of time. They kill the antimicrobial resistant (AMR) bacteria and fungi alone and as "potentiators" of very low doses (sub-MIC) of otherwise ineffective antibiotics, including Penicillin, to kill the AMR "Superbug" pathogens.
Biofilm is the first resistance response of microorganisms to protect themselves against environmental stresses and is associated with most infections and diseases. Removal of biofilm by surface scraping, UV, heat, biocides and antibiotics, etc. signal to the underlying microorganisms when and how fast to build a thicker biofilm shield.
The U.S. Centers for Disease Control (CDC) associate biofilm with 90% of hospital-acquired infections, such as those caused by contamination on indwelling medical devices, ventilators, and water and air systems. The CDC recently reported that 20% of U.S. COVID deaths were due to these secondary infections. Additional life-threatening infections are increasingly traced to biofilm in air and water systems in institutional and commercial buildings and homes. For example, Legionnaire’s Disease, which claimed 17 lives, was traced to biofilm in a hotel’s air conditioners that became aerosolized and inhaled. It is no coincidence that every pathogen on the CDC and WHO lists of urgent threats, pandemic threats, and bioterrorist threats is a biofilm-former. Every drug-resistant “Superbug” strain is a biofilm-former and is considered incurable. Additionally, several microbial species are captures in the same biofilm, increasing the incidence of horizontal gene transfer (Li et al., 2001; Angles et al., 1993; Dunny et al., 1995) and spawning the emergence of new antimicrobial-resistant (AMR) strains.
There are few remedies for biofilm. Physical removal (sterilization, scraping, UV) works for a short-term (e.g., biofilm was recorded on a titanium plate within 30 seconds of sterilization). Biocides (antiseptics, disinfectants, antimicrobials, and antibiotics) are designed to kill free-floating (planktonic), actively growing microorganisms, and the dose of needed to disrupt a biofilm is approximately 1000x the concentrations that are effective against planktonic bacteria (Raffa et al., 2003), which is a dose that is lethal to humans. The overuse of biocides and antibiotics has contributed to the emergence of the AMR Superbugs – and left a cumulative and persistent environmental footprint. Natural antimicrobials, such as silver and other metals, are expensive and eventually trigger the formation of thicker biofilm, resulting in the loss of efficacy over time.

Alykomed Global Solutions LLC (AGSL), based in New York, is a respected and established provider of strategic personalized corporate solutions to the Biopharma industry. Our clients embody a wide range of companies, from innovative startups to larger established, public companies. Our projects include global business development, financial, investment, and capital support, and scientific based endeavors, among others. We are committed to our clients’ long term success, optimized growth strategies, and profitability potential.

We proudly apply our deep scientific knowledge, and combine this with our strong corporate and business development experience and an extensive scientific/business network. Our established and trusted financial investment banking service/registered broker partner, provides our clients with targeted capital and financial solutions and extensive access to institutional and retail investors. These capital services cover a wide range of investment opportunities and offerings, including, but not limited to IPOs and securities offerings, private placements, mergers and acquisition, bank and debt financing etc.

We also undertake strategic growth initiatives through global business development, researching scientific and drug development platforms, assisting with internal valuations, or assistance with other projects- we offer knowledge, experience, leadership, global awareness, and creativity. We work with a global network of professionals, having done business in North America, UK/Europe, and Asia, especially within the United States, Japan, South Korea, and China.

Aphios®, which means “virus-free” in Greek, is an emerging growth biotechnology company developing green enabling technology platforms for improving drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety in an environmentally-sustainable manner, and enhanced therapeutics for the treatment of infectious diseases, CNS disorders, cancers and supportive care.

Our lead product is Zindol® which has successfully completed a Phase 2/3 clinical trial as an adjuvant to conventional 5-HT3 anti-emetics in cancer patients undergoing chemotherapy. Other clinical products under development are APH-0812 for HIV latency and APH-1104 for Alzheimer’s disease. We have several preclinical leads in development for prostate, breast and pancreatic cancer, cancer pain and infectious diseases.

Our lead platform is CFI™ for the manufacture of virus-free biologics such as convalescent COVID-19 plasma, human plasma proteins and monoclonal antibodies as well as viral vaccines against influenza. Our drug discover discovery platform is being harnessed to develop antiviral therapeutics against the novel coronavirus and our nanotechnology platforms are being used to improve the delivery of HIV latency and Alzheimer’s disease therapeutics.

We are raising capital to conduct pivotal Phase 3 clinical trials of Zindol® for CINV to complete clinical development of Zindol and file an NDA with the FDA. In subsequent financings, which will include an IPO, we plan to raise an additional capital to commercialize Zindol® for CINV and develop other indications.

We are a European oncology start-up developing an entirely novel platform of small molecule drugs to cure currently untreatable cancers.We wholly own a pipeline of molecules that are active via novel mechanisms in cancer and several other therapeutic areas.
The mechanism of action of our lead drug, Ag5, targets cancer cells generating high levels of Reactive Oxygen Species (ROS). High ROS tumours are, in general, untreatable. This group of cancers includes KRAS-mutation driven cancers, which comprise around 30% of all cancer cases, and the worst prognosis group. There is currently no treatment for KRAS mutant cancers, which lead to more than 1 million deaths worldwide every year.
Glioblastoma Multiforme (GBM), the commonest primary brain cancer, is also a high-ROS cancer, despite the absence of mutated KRAS. There have been no new treatment options in GBM for 20 years, and prognosis is poor-averaging 18 months.
We have a follow-on compound and a pipeline of innovative molecules addressing both cancer and non-cancerous conditions.
We are raising a series A round which will allow us to gain clinical proof of concept.

Articulate Labs builds wearable medical devices amplify muscle growth throughout everyday activity to help others conquer functional limitations and to restore physical capability